Search
Zafirlukast
go.drugbank.com/drugs/DB00549ApprovedIt is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate, 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamideSulfasalazine
go.drugbank.com/drugs/DB00795ApprovedInvestigational[A255582] Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). … [A255582] Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability.
Synonyms: 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid, 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acidProducts: SAZOPIN TABLET 500 MG, ROSULFANT® 500 MGOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigational[A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized.
Synonyms: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid, 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acidMixtures: ILTUXAM ® 20 MG - 10 MG, OLMETECANLO 40 MG / 10 MGVecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or
Products: NORCURON 10 MG, BROMURODE VECURONIO 10 MGOctinoxate
go.drugbank.com/drugs/DB09496ApprovedInvestigationalIt was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun.
Mixtures: Isa Knox Ageless Serum Makeup Base 10, Impact Fix Essence Make Up Base SPF 10, No. 1Products: Soo Rye Han Dabityun Jiyoon Base 10, Soo Rye Han Dabityoon Jiyoon Base 70Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigational[A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Products: FERRISITA 107,7 MG/5 ML SURUP, 150 MLAlpha-1-proteinase inhibitor
go.drugbank.com/drugs/DB00058ApprovedInvestigationalHuman alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Synonyms: Alpha-1 MP, 122320-05-2Products: PROLASTIN C 1000 MG IV İNFÜZYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADET, Prolastin 1000 mg - Pulver und Lösungsmittel zur Herstellung einer InfusionslösungAmprenavir
go.drugbank.com/drugs/DB00701ApprovedWithdrawnAmprenavir is a protease inhibitor used to treat HIV infection.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: AGENERASE®CAPSULA 150 MG, AGENERASE ® SOLUCION ORAL 15 MG/ML.Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalKnown adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. … Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Tositin 10 mg Film Kaplı Tablet, 56 ADET, JANTY 5 MG FİLM KAPLI TABLET, 56 ADETNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy
Products: Tysabri 150 mg SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (2 adet), TYSABRI 300 MG I.V. INFUZYON ICIN KONSANTRE COZELTI ICEREN FLAKON, 1 ADET